Close menu




November 20th, 2020 | 11:20 CET

BioNTech, Saturn Oil & Gas, Moderna - these stocks will explode!

  • Investments
Photo credits: pixabay.com

Now it's all happening at once with the news in the race against the Corona pandemic. According to BioNTech and its US competitor Moderna, first deliveries of the vaccine are scheduled for the end of this year and the start of 2021. The first step towards normality, even though the head of BioNTech, Ugur Sahin, does not expect a normal social life until the end of 2021 at the earliest. Then, if everything goes smoothly, badly shaken industries should experience an unprecedented renaissance, and their share prices should take off.

time to read: 2 minutes | Author: Stefan Feulner
ISIN: CA80412L1076 , US09075V1026 , US60770K1079

Table of contents:


    Oil in a deep sleep

    The economy in partial lockdown, planes on the ground and hotels closed. The rapid economic downturn has shaken the oil industry to its core. Traces of the downturn can be seen on the chart of Brent oil. 1 barrel cost almost USD 68.00 in October 2019 and then came Corona. At the low point, the price was USD 27.00 but is currently stabilizing at just under USD 42.00. The reason for the stabilization is the imminent prospect of quickly approved vaccines.

    Analysts optimistic

    According to the analysts, the turnaround is imminent. Citigroup's experts assume that the global oil demand will reach the pre-Corona level by the end of 2021. At Fitch Solutions, too, the situation remains relaxed. It confirmed its forecast for the price of Brent oil through 2024 at the end of October. Analysts expect Brent to cost an average of USD 44.0 per barrel in 2020, USD 51.0 per barrel in 2021, USD 53.0 per barrel in 2022, USD 55.0 per barrel in 2023 and USD 58.0 per barrel in 2024.

    Cheapest oil producer in Canada

    In comparison to industry giants such as Exxon Mobil, Shell, BP, who all quote production costs of more than USD 30 per barrel, the Canadian oil producer Saturn Oil & Gas pays only a measly USD 12 per barrel. These low costs made the Calgary-based Company by far the cheapest oil producer in Canada in 2019.

    Falling prices as an opportunity

    If the CEO of Saturn Oil & Gas John Jeffrey has his way, production costs are to be kept within this range. Since own drilling programs tend to be more complex and expensive, the management's strategy is based on inorganic growth, i.e. the acquisition of exciting competitors that have an attractive risk/reward profile due to the crisis. The ambitious goal of Saturn Oil & Gas is to become an innovation leader in the oil and gas industry.

    Management trimmed for growth

    In addition to the appointment of the experienced Wendy Woolsey as interim CFO, the management of Saturn Oil & Gas has achieved another coup. Jean-Pierre Colin joins the team as the senior strategy consultant. Colin is regarded in the industry as one of the great minds due to his incredibly successful career. Among other things, Colin has advised several high-ranking politicians in the Canadian federal government and the Privy Council of Canada on five acquisitions of the country's largest oil and gas companies in the 1980s by Petro-Canada. Colin also served on the boards of many successful junior commodities companies, including Pelangio Mines Inc. and Virginia Gold Inc. which sold its Eleonor project for more than $1 billion to Goldcorp Inc., now known as Newmont Corporation.

    Clear objectives

    The newcomer was relatively clear about its objectives: "Saturn Oil & Gas represents a unique opportunity to build an acquisition vehicle for oil and gas that offers inorganic growth opportunities and returns for its shareholders and other key stakeholders". The current market capitalization of Saturn Oil & Gas is just under EUR 15 million. It is probably only a matter of time before the first success stories are reported on the tickers. Since the last announcement, there has been a noticeable increase in trading volume at ever-higher prices. The share price on the TSXV is currently CAD 0.12. A sustained break-out through the resistance at CAD 0.14 should result in significantly higher prices.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read